2017 Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: A Joint Consensus Document from EHRA and ESC Working Group on Thrombosis | Heart Rhythm Society

2017 Antithrombotic Therapy in Atrial Fibrillation Associated with Valvular Heart Disease: A Joint Consensus Document from EHRA and ESC Working Group on Thrombosis

The Heart Rhythm Society affirmed the value of the document on June 8, 2017.

August 30, 2017—This consensus document was developed by the European Heart Rhythm Association (EHRA) and the European Society of Cardiology (ESC) Working Group on Thrombosis, with representation from the ESC Working Group on Valvular Heart Disease, Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), South African Heart Association (SA Heart), and SOLAECE, and addresses management of patients with atrial fibrillation and associated valvular heart disease (VHD), with up-to-date consensus recommendations for clinical practice for different forms of VHD. 

HRS Endorsed / Affirmed
Atrial Fibrillation